Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden

Brain

Volumn 133, Issue 2, 2010, Pages 512-528

  Rabinovici, Gil D ^a,b,c,e   Furst, Ansgar J ^b,c,e   Alkalay, Adi ^a,b   Racine, Caroline A ^a   O'Neil, James P ^c,e   Janabi, Mustafa ^c,e   Baker, Suzanne L ^b,c,e   Agarwal, Neha ^b   Bonasera, Stephen J ^a   Mormino, Elizabeth C ^b,c,e   Weiner, Michael W ^d,e   Gorno Tempini, Maria L ^a   Rosen, Howard J ^a   Miller, Bruce L ^a   Jagust, William J ^a,b,c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

11C labelled Pittsburgh compound B; 18F labelled fluorodeoxyglucose; Age of onset; Alzheimer's disease; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN MAPPING; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FRONTAL CORTEX; GLUCOSE METABOLISM; GROUPS BY AGE; HUMAN; IN VIVO STUDY; MALE; MINI MENTAL STATE EXAMINATION; NATIONAL INSTITUTE OF NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE AND THE ALZHEIMER DISEASE AND RELATED DISORDERS ASSOCIATION CRITERIA; NEUROIMAGING; NEUROLOGIC EXAMINATION; OCCIPITAL CORTEX; PARIETAL LOBE; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN METABOLISM; SYMPTOM; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; ENERGY METABOLISM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 77249098331     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp326     Document Type: Article

References (102)

1. Agosta F, Vossel KA, Miller BL, Migliaccio R, Bonasera SJ, Filippi M, et al. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci USA 2009; 106: 2018-2022
2. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007; 64: 431-434
3. Barclay LL, Zemcov A, Blass JP, McDowell FH. Factors associated with duration of survival in Alzheimer's disease. Biol Psychiatry 1985; 20: 86-93. (Pubitemid 16051971)
4. Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998; 55: 326-335
5. Bigio EH, Hynan LS, Sontag E, Satumtira S, White CL. Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol Appl Neurobiol 2002; 28: 218-227
6. Binetti G, Magni E, Padovani A, Cappa SF, Bianchetti A, Trabucchi M. Neuropsychological heterogeneity in mild Alzheimer's disease. Dementia 1993; 4: 321-326
7. Bird TD, Stranahan S, Sumi SM, Raskind M. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann Neurol 1983; 14: 284-293
8. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 2009; 30: 1895-1901
9. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259
10. Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 2009; 29: 1860-1873
11. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-7717
12. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005; 48: 913-922
13. Daselaar SM, Prince SE, Cabeza R. When less means more: deactivations during encoding that predict subsequent memory. Neuroimage 2004; 23: 921-927
14. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009; 72: 1487-1494
15. Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, et al. Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 2005; 64: 102-107
16. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501-508
17. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-2866
18. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipo-protein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349-1356
19. Filley CM, Kelly J, Heaton RK. Neuropsychologic features of early-and late-onset Alzheimer's disease. Arch Neurol 1986; 43: 574-576
20. Frisoni GB, Pievani M, Testa C, Sabattoli F, Bresciani L, Bonetti M, et al. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 2007; 130: 720-730
21. Frisoni GB, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso MP. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric study. J Neurol Neurosurg Psychiatry 2005; 76: 112-114
22. Fujimori M, Imamura T, Yamashita H, Hirono N, Ikejiri Y, Shimomura T, et al. Age at onset and visuocognitive disturbances in Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 163-166 (Pubitemid 29154984)
23. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Locascio JJ, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996; 39: 62-70.
24. Grady CL, Haxby JV, Horwitz B, Berg G, Rapoport SI. Neuropsychologi-cal and cerebral metabolic function in early vs late onset dementia of the Alzheimer type. Neuropsychologia 1987; 25: 807-816
25. Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex 2009; 19: 72-78
26. Hansen LA, DeTeresa R, Davies P, Terry RD. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. Neurology 1988; 38: 48-54.
27. Hedden T, Van Dijk KR, Becker JA, Mehta A, Sperling RA, Johnson KA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009; 29: 12686-12694
28. Heyman A, Wilkinson WE, Hurwitz BJ, et al. Early-onset Alzheimer's disease: clinical predictors of institutionalisation and death. Neurology 1987; 27: 980-984.
29. Hirono N, Hashimoto M, Yasuda M, Ishii K, Sakamoto S, Kazui H, et al. The effect of APOE epsilon4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002; 58: 743-750
30. Ho GJ, Hansen LA, Alford MF, Foster K, Salmon DP, Galasko D, et al. Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Neuroreport 2002; 13: 1825-1828
31. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-1645
32. Imamura T, Takatsuki Y, Fujimori M, Hirono N, Ikejiri Y, Shimomura T, et al. Age at onset and language disturbances in Alzheimer's disease. Neuropsychologia 1998; 36: 945-949 (Pubitemid 28404321)
33. Ishii K, Kawachi T, Sasaki H, Kono AK, Fukuda T, Kojima Y, et al. Voxel-based morphometric comparison between early-and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. AJNR Am J Neuroradiol 2005; 26: 333-340
34. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-1365
35. Jacobs D, Sano M, Marder K, Bell K, Bylsma F, Lafleche G, et al. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994; 44: 1215-1220
36. Jagust WJ, Reed BR, Seab JP, Budinger TF. Alzheimer's disease: age at onset and single-photon emission computed tomographic patterns of regional cerebral blood flow. Arch Neurol 1990; 47: 628-633
37. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989; 135: 309-319
38. Karas G, Scheltens P, Rombouts S, van Schijndel R, Klein M, Jones B, et al. Precuneus atrophy in early-onset Alzheimer's disease: a morpho-metric structural MRI study. Neuroradiology 2007; 49: 967-976
39. Kemp PM, Holmes C, Hoffmann SM, Bolt L, Holmes R, Rowden J, et al. Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia. J Neurol Neurosurg Psychiatry 2003; 74: 715-719
40. 11C]PIB uptake in Alzheimer disease. Neurology 2006; 67: 1575-1580
41. Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, et al. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain 2005; 128: 1790-1801
42. Klein GJ, Teng X, Jagust WJ, Eberling JL, Acharya A, Reutter BW, et al. A methodology for specifying PET VOI's using multimodality techniques. IEEE Trans Med Imaging 1997; 16: 405-415
43. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319 (Pubitemid 38269583)
44. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003; 23: 2086-2092
45. Knopman DS, Petersen RC, Edland SD, Cha RH, Rocca WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology 2004; 62: 506-508
46. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 2009; 65: 650-657
47. Koss E, Edland S, Fillenbaum G, Mohs R, Clark C, Galasko D, et al. Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: A CERAD analysis, Part XII. Neurology 1996; 46: 136-141
48. Kramer JH, Jurik J, Sha SJ, Rankin KP, Rosen HJ, Johnson JK, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol 2003; 16: 211-218
49. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65: 1304-1309
50. Li Y, Nowotny P, Holmans P, Smemo S, Kauwe JS, Hinrichs AL, et al. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci USA 2004; 101: 15688-15693
51. Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci USA 2008; 105: 4441-4446
52. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007; 130: 2607-2615
53. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996; 27: 1274-1282
54. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-1972
55. Loring DW, Largen JW. Neuropsychological patterns of presenile and senile dementia of the Alzheimer type. Neuropsychologia 1985; 23: 351-357
56. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 5644-5651
57. Mann DM, Yates PO, Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol 1984; 10: 185-207.
58. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer's disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol 2007; 20: 29-33.
59. 11C-labeled 6-substituted 2-arylbenzothia-zoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-2754
60. McKhann G, Drachman DA, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944
61. Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999; 40: 2053-2065
62. Meltzer CC, Leal JP, Mayberg HS, Wagner HN Jr, Frost JJ. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr 1990; 14: 561-570
63. Mercy L, Hodges JR, Dawson K, Barker RA, Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology 2008; 71: 1496-1499
64. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, et al. APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer disease. Nat Genet 1998; 19: 321-322
65. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995; 19: 541-547
66. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Annals of Neurology 1997; 42: 85-94.
67. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452
68. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486
69. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009; 132: 1310-1323
70. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules [see comments]. Neurology 1993; 43: 2412-2414
71. Morris JC, Roe CM, Xiong C, Fagan AM, Holtzman DM, Mintun MA. APOE predicts abeta but not tau Alzheimer's pathology in cognitively normal aging. Annals of Neurology 2009; in press.
72. Mortimer JA, Ebbitt B, Jun SP, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992; 42: 1689-1696
73. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000; 20: 4050-4058
74. Mueller SG, Laxer KD, Barakos J, Cheong I, Garcia P, Weiner MW. Widespread neocortical abnormalities in temporal lobe epilepsy with and without mesial sclerosis. Neuroimage 2009; 46: 353-359
75. Nochlin D, van Belle G, Bird TD, Sumi SM. Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer's disease. Alzheimer Dis Assoc Disord 1993; 7: 212-222
76. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-1547
77. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-1212
78. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of fron-totemporal dementia. Neurology 2002; 58: 1615-1621
79. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E [see comments]. New England J Med 1996; 334: 752-758
80. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106: 6820-6825
81. Rocchi A, Pellegrini S, Siciliano G, Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull 2003; 61: 1-24.
82. Rosen HJ, Gorno-Tempini ML, Goldman WP, Perry RJ, Schuff N, Weiner M, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002; 58: 198-208.
83. Rosen RF, Ciliax BJ, Wingo TS, Gearing M, Dooyema J, Lah JJ, et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol 2009; Aug 19 [Epub ahead of print].
84. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J (Clin Res Ed) 1984; 288: 961-964
85. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725
86. Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, et al. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci 2002; 200: 27-32.
87. Salmon E, Collette F, Degueldre C, Lemaire C, Franck G. Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease. Hum Brain Mapp 2000; 10: 39-48.
88. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-2309
89. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204
90. Seltzer B, Sherwin I. A comparison of clinical features in early-and late-onset primary degenerative dementia. One entity or two? Arch Neurol 1983; 40: 143-146
91. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2009; Oct 13. [Epub ahead of print].
92. Shiino A, Watanabe T, Kitagawa T, Kotani E, Takahashi J, Morikawa S, et al. Different atrophic patterns in early-and late-onset Alzheimer's disease and evaluation of clinical utility of a method of regional z-score analysis using voxel-based morphometry. Dement Geriatr Cogn Disord 2008; 26: 175-186
93. Shiino A, Watanabe T, Maeda K, Kotani E, Akiguchi I, Matsuda M. Four subgroups of Alzheimer's disease based on patterns of atrophy using VBM and a unique pattern for early onset disease. Neuroimage 2006; 33: 17-26.
94. Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex 2007; 43: 835-845
95. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63: 178-188
96. Sun FT, Schriber RA, Greenia JM, He J, Gitcho A, Jagust WJ. Automated template-based PET region of interest analyses in the aging brain. Neuroimage 2007; 34: 608-617
97. Svoboda E, McKinnon MC, Levine B. The functional neuroanatomy of autobiographical memory: a meta-analysis. Neuropsychologia 2006; 44: 2189-2208
98. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-289
99. Wagner AD, Shannon BJ, Kahn I, Buckner RL. Parietal lobe contributions to episodic memory retrieval. Trends Cogn Sci 2005; 9: 445-453
100. Walsh DM, Selkoe DJ. A beta oligomers-a decade of discovery. J Neurochem 2007; 101: 1172-1184
101. West MJ. New stereological methods for counting neurons. Neurobiol Aging 1993; 14: 275-285
102. Yasuno F, Imamura T, Hirono N, Ishii K, Sasaki M, Ikejiri Y, et al. Age at onset and regional cerebral glucose metabolism in Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9: 63-67 (Pubitemid 28081685)